Novel therapeutics from breakthrough research

in gastrointestinal disorders and diseases    

Synergy Pharmaceuticals, Inc. (SGYP.OB) is a public, development-stage biopharmaceutical company that develops drugs to treat gastrointestinal (GI) conditions and diseases. 

Our patented drug candidates, currently in clinical development, were discovered and developed in-house by Synergy scientists.

The company has its headquarters in New York City and also operates a research laboratory in Doylestown, PA that supports Synergy’s drug development programs.

January 22, 2010

Synergy Pharmaceuticals to Present at the 8th Annual BioPartnering North America (BPN) Conference in Vancouver, BC, Canada

December 11, 2009

Synergy Pharmaceuticals announced that it has completed a private placement in which it raised gross proceeds of an aggregate $8.6 million

October 8, 2009

Synergy Pharmaceuticals Announces Appointment of Dr. Alan F. Joslyn

October 5, 2009

Synergy Pharmaceuticals to Present at the 17th Annual BioPartnering Europe Conference

July 7, 2009

Synergy Pharmaceuticals Raises $7.09 Million in Common Stock Financing

Synergy’s drug development program and patent estate are based on a class of synthetic peptides designed to mimic uroguanylin, a human hormone that regulates intestinal fluid transport.

Synergy has a lead drug, SP-304, in clinical development, to treat chronic constipation (CC) and constipation-predominant irritable bowel syndrome (IBS-C). A second drug, SP-333, is in pre-clinical development for GI diseases.

Synergy Highlights

Development Program & Lead Drug: SP-304

The market opportunity for gastrointestinal therapeutics was recently valued at around $50 BN in 2008. The US market which comprises almost 40% of the estimated global market is worth almost $19 BN.

Chronic constipation and IBS-C have a wide prevalence, affecting up to 15% and 20% of the population respectively. More than 100 million people worldwide suffer from these conditions.

Gastrointestinal Disorders (GI)  & Diseases